The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cancer: A preliminary analysis

European Journal of Cancer Part A

Volumn 32, Issue 9, 1996, Pages 1490-1497

  Van Der Wall, E ^a,b   Schaake Koning, C C E ^a   Van Zandwijk, N ^a   Baars, J W ^a   Schornagel, J H ^a   Richel, D J ^a,c   Rutgers, E J T ^a   Borger, J H ^a   Beijnen, J H ^a   Rodenhuis, S ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

Adjuvant; Haematologic toxicity; High dose chemotherapy; High risk breast cancer; Pneumonitis; Radiation

Indexed keywords

CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; PREDNISONE; THIOTEPA;

ADJUVANT THERAPY; ADULT; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RADIATION PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; STEM CELL TRANSPLANTATION;

EID: 9444269793     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00129-3     Document Type: Article

References (33)

1. 1. Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993, 11, 1132-1143.
2. 2. Mulder NH, Sleijfer DTh, De Vries EGE, et al. Intensive chemotherapy with autologous bone marrow reinfusion in patients with breast cancer and more than 5 involved lymph nodes. Proc Am Soc Clin Oncol 1993, 12, 104 (Abstr.).
3. 3. Gianni AM, Siena A, Bregni M, et al. Growth factor supported high-dose sequential (HDS) adjuvant chemotherapy in breast cancer with ≥10 positive nodes. Proc Am Soc Clin Oncol 1992, 11, 60 (Abstr.).
4. 4. Overgaard M, Christensen JJ, Johansen H, et al. Evaluation of radiotherapy in high-risk breast cancer patients: report from the Danish Breast Cancer Cooperative Group (DBCG 82) Trial. Int J Radiat Oncol Biol Phys 1990, 19, 1121-1124.
5. 5. Griem KL, Henderson IC, Gelman R, et al. The five-year results of a randomized trial of adjuvant irradiation therapy after chemotherapy in breast cancer patients treated with mastectomy. J Clin Oncol 1987, 5, 1546-1555.
6. 6. Marks LB, Halperin EC, Prosnitz LR, et al. Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with ≥10 positive axillary lymph nodes. Int J Radiat Oncol Biol Phys 1992, 23, 1021-1026.
7. 7. Marks LB, Rosner GL, Prosnitz LR, Ross M, Vredenburgh JJ, Peters WP. The impact of conventional plus high-dose chemotherapy with autologous bone marrow transplantation on hematologic toxicity during subsequent local-regional radiotherapy for breast cancer. Cancer 1994, 74, 2964-2971.
8. 8. Gross NJ. Pulmonary effects of radiation therapy. Ann Intern Med 1977, 86, 81-92.
9. 9. Lingos TI, Recht A, Vicini F, Abner A, Silver B, Harris JR. Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys 1991, 21, 355-360.
10. 10. Philips TL, Wharam MD, Margolis LW. Modification of radiation injury to normal tissues by chemotherapeutic agents. Cancer 1975, 35, 1678-1684.
11. 11. Phillips GL, Fay JW, Herzig GP, et al. Intensive 1,3-bis(2-chloroethyl)-1-nitrosurea (BCNU), NSC#4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study. Cancer 1983, 52, 1792-1802.
12. 12. O'Driscoll BR, Hasleton PS, Taylor PM, Poulter LW, Gattamaneni HR, Woodcock AA. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med 1990, 232, 378-382.
13. 13. Aronin PA, Mahaley MS Jr, Rudnick SA, et al. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas. N Engl J Med 1980, 303, 183-188.
14. 14. Litam JP, Dail DH, Spitzer G, et al. Early pulmonary toxicity after administration of high-dose BCNU. Cancer Treat Rep 1981, 65, 39-44.
15. 15. Muggia FM, Louie AC, Sikic BI. Pulmonary toxicity of antitumor agents. Cancer Treat Rev 1983, 10, 221-243.
16. 16. Cooper JAD, White DA, Matthay RA. Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. Am Rev Respir Dis 1986, 133, 321-340.
17. 17. Lombard CM, Churg A, Winokur S. Pulmonary veno-occlusive disease following therapy for malignant neoplasms. Chest 1987, 92, 871-876.
18. 18. Todd NW, Peters WP, Ost AH, Roggli VL, Piantadosi CA. Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous marrow transplantation. Am Rev Respir Dis 1993, 147, 1264-1270.
19. 19. Jones RB, Matthes S, Shpall E, et al. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin and carmustine: pharmacodynamic evaluation of carmustine. J Natl Cancer Inst 1993, 85, 640-647.
20. 20. Rodenhuis S, Baars JW, Schornagel JH, et al. Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantation incorporating carboplatin, cyclophosphamide and thiotepa. Ann Oncol 1992, 3, 855-860.
21. 21. van der Wall E, Nooijen WJ, Baars JW, et al. High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach. Br J Cancer 1995, 71, 857-862.
22. 22. Rodenhuis S, Van der Wall E, Ten Bokkel Huinink WW, Schornagel JH, Richel DJ, Vlasveld LT. Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancer. Cancer Invest 1995, 13, 355-362.
23. 23. Van Dongen JA. Subclavicular biopsy as a guideline for the treatment of breast cancer. World J Surg 1977, 1, 306-308.
24. 24. Van der Wall E, Richel DJ, Musumanto YH, et al. Feasibility study of FEC-chemotherapy with dose-intensive epirubicin as initial treatment in high-risk breast cancer. Ann Oncol 1993, 4, 791-792.
25. 25. van der Wall E, Richel DJ, Holtkamp MJ, et al. Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size. Ann Oncol 1994, 5, 795-802.
26. 26. Quanjer PH, Andersen LH, Tammeling GJ. Clinical respiratory physiology. Bull Europ Physiopath Resp 1983, 19(Suppl. 5), 11-21.
27. 27. Eder JP, Elias A, Shea TC, et al. A phase I-II study of cyclophosphamide, thiotepa and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol 1990, 8, 1239-1245.
28. 28. Antman K, Ayash L, Elias A, et al. A phase II study of high-dose cyclophosphamide, thiotepa and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992, 10, 102-110.
29. 29. Ayash LJ, Elias A, Wheeler C, et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994, 12, 37-44.
30. 30. Rothwell RI, Kelly SA, Joslin CA. Radiation pneumonitis in patients treated for breast cancer. Radiother Oncol 1985, 4, 9-14.
31. 31. Kaufman J, Gunn W, Hartz AJ, et al. The pathophysiologic and roentgenologic effects of chest irradiation in breast carcinoma. Int J Radiat Oncol Biol Phys 1986, 12, 887-893.
32. 32. Gillam PMS, Heaf PJD, Hoffbrand BI, et al. Chronic bronchitis and radiotherapy of the lung. Lancet 1964, 1, 1245-1248.
33. 33. Hoffbrand BI, Gillman PMS, Heaf PJD. Effect of chronic bronchitis on changes in pulmonary function caused by irradiation of the lungs. Thorax 1965, 20, 303-308.